Helix

Helix serves three groups: health systems and clinicians who order diagnostic genetic tests and deploy population-screening programs, payers that manage genomic benefit costs through the Genomic Advantage program, and life-sciences companies that license de-identified clinico-genomic data from the Helix GenoSphere database for drug discovery and clinical-trial support. The firm publicly names partners such as Alnylam Pharmaceuticals and Mawi DNA Technologies.

Helix sells clinical testing services to healthcare providers and health systems, integrating results directly into electronic health records. The firm also sells population-genomics infrastructure to payers, helping them manage the cost and utilization of genomic benefits across covered lives. Specific pricing models and revenue splits are not publicly disclosed.

The Helix Research Network is a consortium of health systems that run large-scale genomics programs on Helix's platform. Patients in participating systems contribute genetic and longitudinal clinical data, which — after de-identification — becomes part of the research database that Helix licenses to life-sciences partners. Helix markets this network as a way to accelerate novel discoveries while embedding genomic screening into routine care.

Helix provides access to what it describes as the world's largest clinico-genomic database: de-identified genetic sequences linked to 13-plus years of longitudinal medical records. Pharmaceutical partners use this dataset for target identification, patient-stratification models, clinical-trial recruitment, and real-world evidence generation. The data is commercialized through Helix GenoSphere, with governance and consent managed by the underlying health-system agreements.

Helix operates as both. It runs a clinical diagnostics business with seamless EHR integration and ordering workflows for clinicians, and it simultaneously aggregates the resulting genetic and phenotypic data into a research database that it licenses to pharmaceutical and biotech companies. This dual model means routine clinical care generates the raw material for Helix's data-licensing revenue.

Helix itself does not develop drugs. Its role is to provide clinico-genomic data and population-genomics infrastructure that pharmaceutical partners use to accelerate their own R&D. The May 2026 agreement with Alnylam illustrates the model: Helix supplies data and platform capabilities to support Alnylam's precision-medicine programs, but Helix does not hold any drug assets or run clinical trials.

Sample collection occurs primarily through partner health systems in the United States, where patients provide samples during routine clinical encounters. Helix also supports remote collection internationally via partners such as Mawi DNA Technologies, which supplies non-invasive buccal swab technology that complements existing collection methods and broadens participation in population-genomics initiatives.